Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
Immunological Mechanisms Underlying Mucosal IgE Responses
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 50
- Registration Number
- NCT06234761
- Locations
- 🇧🇪
University Hospital Gent, Gent, Belgium
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Akron Children's Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT06226610
- Locations
- 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States
A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06192563
- Locations
- 🇮🇹
Investigational Site Number: 002, Bologna, Italy
🇮🇹Investigational Site Number: 006, Brescia, Italy
🇮🇹Investigational Site Number: 004, Firenze, Italy
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT06191315
- Locations
- 🇺🇸
Phoenix Children's Hospital- Site Number : 8400001, Phoenix, Arizona, United States
🇫🇷Investigational Site Number : 2500001, Lille, France
🇫🇷Investigational Site Number : 2500004, Nice, France
Early-onset Dupilumab Effects in CRSwNP
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- University of Rochester
- Registration Number
- NCT06188871
- Locations
- 🇺🇸
University of Rochester Department of Otolaryngology Head and Neck Surgery, Rochester, New York, United States
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 500
- Registration Number
- NCT06169527
- Locations
- 🇫🇷
Investigational Site Number: 2500048, Levallois-Perret, France
🇫🇷Investigational Site Number: 2500041, Amiens, France
🇫🇷Investigational Site Number: 2500037, Angers, France
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 64
- Registration Number
- NCT06101095
- Locations
- 🇮🇱
Investigational Site Number : 3760003, Tel Aviv, Israel
🇨🇭Investigational Site Number : 7560001, Wetzikon, Switzerland
🇮🇱Investigational Site Number : 3760002, Haifa, Israel
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 10
- Registration Number
- NCT06012448
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-31
- Target Recruit Count
- 216
- Registration Number
- NCT06004986
- Locations
- 🇳🇱
Amsterdam University Medical Centers, Amsterdam, Noord-Holland, Netherlands
🇳🇱Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 300
- Registration Number
- NCT05991323
- Locations
- 🇺🇸
Medical Dermatology Specialists Site Number : 8400005, Phoenix, Arizona, United States
🇺🇸Medical Dermatology Specialists- Site Number : 8400005, Phoenix, Arizona, United States
🇺🇸Saguaro Dermatology Associates, LLC - Probity - PPDS- Site Number : 8400024, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.